Immune checkpoint inhibitors: Significant advancements in non–small cell lung cancer treatment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitors: Significant advancements in non–small cell lung cancer treatment
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-02-13
DOI
10.1093/ajhp/zxab041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
- (2020) Enriqueta Felip et al. EUROPEAN JOURNAL OF CANCER
- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- (2020) Francesco Facchinetti et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
- (2020) Gary Middleton et al. Lancet Respiratory Medicine
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
- (2019) Alessio Cortellini et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer
- (2019) Eugene Muchnik et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
- (2019) Yara van Holstein et al. DRUGS & AGING
- Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
- (2019) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer
- (2019) Ganessan Kichenadasse et al. JAMA Oncology
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
- (2018) Muhammad Khan et al. MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)
- (2018) R S Herbst et al. ANNALS OF ONCOLOGY
- 1472PImmunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience
- (2018) A Luciani et al. ANNALS OF ONCOLOGY
- Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment
- (2018) Lizza E. L. Hendriks et al. Frontiers in Oncology
- Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
- (2018) Shirish M. Gadgeel et al. LUNG CANCER
- P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
- (2017) David Spigel et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer
- (2016) Saad A. Khan et al. JAMA Oncology
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Immunotherapy in the treatment of non-small cell lung cancer
- (2014) Raghav Sundar et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started